Myocarditis following COVID-19 mRNA vaccination
Kanak Parmar, Poemlarp Mekraksakit, Gaspar Del Rio‐Pertuz, Pooja Sethi, Arunee Motes, Megan L. Hughes, Jason Wischmeyer, Luis Carbajal, Erwin Argueta Sosa
Abstract
Messenger RNA vaccines are the main COVID-19 vaccines authorized for use in the United States. Side effects are typically minor and transient. We report a case series of four subjects with an acute myocarditis-like illness following mRNA COVID-19 vaccination who were hospitalized at our hospital in Lubbock, Texas. Three patients were young men who presented with acute chest pain after the second dose of the mRNA-1273 vaccine. Another patient was a 53-year-old white woman who presented with acute left arm pain 3 days after the first dose of the mRNA-1273 vaccine. She was later found to have acute decompensated heart failure, and endomyocardial biopsy revealed eosinophilic injury-mediated myocarditis.